What is William Blair's Estimate for NBIX FY2025 Earnings?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Analysts at William Blair lowered their FY2025 EPS estimates for Neurocrine Biosciences in a report released on Monday, July 14th. William Blair analyst M. Minter now expects that the company will post earnings of $3.70 per share for the year, down from their previous estimate of $3.71. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.28 per share.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.70 by ($0.62). Neurocrine Biosciences had a return on equity of 11.81% and a net margin of 12.68%. The firm had revenue of $572.60 million for the quarter, compared to analysts' expectations of $587.06 million. During the same quarter in the previous year, the firm posted $1.20 earnings per share. The company's revenue for the quarter was up 11.1% on a year-over-year basis.

Several other research firms have also recently weighed in on NBIX. HC Wainwright lowered their price objective on shares of Neurocrine Biosciences from $185.00 to $168.00 and set a "buy" rating on the stock in a research report on Tuesday, April 22nd. BMO Capital Markets lifted their target price on shares of Neurocrine Biosciences from $96.00 to $115.00 and gave the company a "market perform" rating in a research note on Tuesday, May 6th. Wall Street Zen lowered Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a report on Thursday, March 20th. Needham & Company LLC lifted their price objective on Neurocrine Biosciences from $138.00 to $139.00 and gave the company a "buy" rating in a research report on Tuesday, May 6th. Finally, Evercore ISI reduced their price objective on Neurocrine Biosciences from $190.00 to $185.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Three investment analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $163.91.

Neurocrine Biosciences Price Performance

NASDAQ NBIX traded up $0.63 on Tuesday, hitting $134.11. 674,476 shares of the stock were exchanged, compared to its average volume of 1,144,569. Neurocrine Biosciences has a 52-week low of $84.23 and a 52-week high of $157.98. The company has a market capitalization of $13.27 billion, a price-to-earnings ratio of 45.46, a P/E/G ratio of 1.35 and a beta of 0.24. The company's 50-day moving average price is $125.18 and its two-hundred day moving average price is $121.53.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of NBIX. Dodge & Cox lifted its position in Neurocrine Biosciences by 83.5% during the 1st quarter. Dodge & Cox now owns 5,534,624 shares of the company's stock worth $612,129,000 after acquiring an additional 2,518,199 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Neurocrine Biosciences by 102.9% during the fourth quarter. Wellington Management Group LLP now owns 1,457,425 shares of the company's stock valued at $198,939,000 after buying an additional 739,199 shares during the last quarter. Thrivent Financial for Lutherans raised its position in shares of Neurocrine Biosciences by 2,759.4% during the fourth quarter. Thrivent Financial for Lutherans now owns 737,772 shares of the company's stock valued at $100,705,000 after buying an additional 711,970 shares during the last quarter. Orbimed Advisors LLC raised its position in shares of Neurocrine Biosciences by 210.4% during the fourth quarter. Orbimed Advisors LLC now owns 938,120 shares of the company's stock valued at $128,053,000 after buying an additional 635,900 shares during the last quarter. Finally, Swedbank AB raised its position in shares of Neurocrine Biosciences by 5,078.9% during the first quarter. Swedbank AB now owns 429,697 shares of the company's stock valued at $47,524,000 after buying an additional 421,400 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company's stock.

Insider Activity

In other Neurocrine Biosciences news, Director William H. Rastetter sold 30,000 shares of the business's stock in a transaction on Monday, May 5th. The shares were sold at an average price of $110.20, for a total transaction of $3,306,000.00. Following the completion of the transaction, the director owned 37,491 shares of the company's stock, valued at $4,131,508.20. The trade was a 44.45% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ingrid Delaet sold 457 shares of the business's stock in a transaction on Thursday, July 10th. The stock was sold at an average price of $135.00, for a total transaction of $61,695.00. Following the transaction, the insider directly owned 4,730 shares of the company's stock, valued at approximately $638,550. This represents a 8.81% decrease in their position. The disclosure for this sale can be found here. Insiders sold 120,251 shares of company stock worth $14,978,602 in the last 90 days. Insiders own 4.80% of the company's stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.